Altemia, Inc. has developed a medical food called Altemia MF, for the treatment of deficiencies associated with Sickle Cell Disease (SCD). SCD is a hereditary genetic disorder where red blood cells containing a highly reactive hemoglobin tend to deform, become inflamed, and clog blood vessels. When this occurs, patients with SCD experience severe episodes of pain and sometimes organ damage. This debilitating disease currently impacts over 100,000 people in the United States alone, and millions worldwide.

 

 In clinical studies, when the deficiency was restored, patients experienced a statistically significant reduction of biomarkers associated with inflammation. In our published clinical trials, Altemia MF addresses fatty acid deficiencies in just a few weeks after supplementation.

 

Launch of the commercial Altemia MF product will initiate in 2025 for select communities under the direct supervision of physicians who treat SCD. Additional clinical trials are planned to broaden the awareness of this disease and its related symptoms.